



UNIVERSITI PUTRA MALAYSIA

***QUANTIFICATION OF BETA-DEFENSIN COPY NUMBER VARIABLE
GENES IN RELATION TO INFLAMMATION IN DIABETIC PATIENTS***

MARYAM JAMIELAH BINTI YUSOFF

FPSK(m) 2015 83



**QUANTIFICATION OF BETA-DEFENSIN COPY NUMBER VARIABLE
GENES IN RELATION TO INFLAMMATION IN DIABETIC PATIENTS**

By

MARYAM JAMIELAH BINTI YUSOFF

**Thesis Submitted to the School of Graduate Studies, Universiti Putra Malaysia,
in Fulfilment of the Requirements for the Degree of Master of Science**

June 2015

COPYRIGHT

All material contained within the thesis, including without limitation text, logos, icons, photographs, and all other artwork, is copyright material of Universiti Putra Malaysia unless otherwise stated. Use may be made of any material contained within the thesis for non-commercial purposes from the copyright holder. Commercial use of material may only be made with the express, prior, written permission of Universiti Putra Malaysia.

Copyright © Universiti Putra Malaysia

DEDICATIONS

This thesis is dedicated to you Ibu and Abah for the continuous support and encouragement throughout the ups and downs in my postgraduate journey.

Abstract of thesis presented to the Senate of Universiti Putra Malaysia in fulfilment of the requirement for the degree of Master of Science

QUANTIFICATION OF BETA-DEFENSIN COPY NUMBER VARIABLE GENES IN RELATION TO INFLAMMATION IN DIABETIC PATIENTS

By

MARYAM JAMIELAH BINTI YUSOFF

June 2015

Chairman : Suhaili binti Abu Bakar @ Jamaludin, PhD
Faculty : Medicine and Health Sciences

Beta-defensins is one of the predominant antimicrobial peptide which serves as the first line defence against broad spectrum of microbes, including fungi and some viruses. These peptides are encoded by beta-defensins gene; which is variable in copy number. Copy number variations (CNVs) of beta-defensins is present in healthy population. Nevertheless, studies from the past decades have found that beta-defensins gene CNVs also contributed to several inflammatory diseases. Therefore, the objective of this study is to investigate the relationship between copy number variation of beta-defensins with inflammatory condition in type 2 diabetes (T2D). It is hypothesised that copy number variation of beta-defensins contributes to development of T2D through modification of immune response products dosage that exert attacks on host cell that contributed to inflammatory condition in T2D patients. DNA samples from 146 control and 392 T2D individuals were extracted for this study. Beta-defensins copy number quantification was carried out by using paralogue ratio test (PRT107A and HSPD21 primers) and validated by indel polymorphism measurement (5DEL primer) and two microsatellite analysis (EPEV-1 and EPEV-3 primers). Based on the analysis, the copy number variation is more extensive in T2D population ranging between 1 and 12 copies; with copy number 1, 10 and 12 detected in nephropathy group, while in control population the copy number varies between 2 and 8 copies. However, the distribution of copy number are not statistically significant between T2D and control ($p=0.209$) and between those with and without nephropathy among T2D population ($p=0.522$). Despite the result, the white blood cell count between individuals with and without nephropathy from T2D population is significantly different ($p=0.000$). In conclusion, future studies are needed to further explore the true potential of copy number variation of beta-defensins gene towards development of nephropathy in T2D patients.

Abstrak tesis yang dikemukakan kepada Senat Universiti Putra Malaysia sebagai memenuhi keperluan untuk ijazah Master Sains

KUANTIFIKASI VARIASI BILANGAN SALINAN GEN BETA-DEFENSINS KE ATAS KERADANGAN DALAM KALANGAN PESAKIT DIABETES

Oleh

MARYAM JAMIELAH BINTI YUSOFF

Jun 2015

Pengerusi : Suhaili binti Abu Bakar @ Jamaludin, PhD
Fakulti : Perubatan dan Sains Kesihatan

Beta-defensins merupakan salah satu peptida antimikrob yang dominan dan berfungsi sebagai barisan pertama pertahanan terhadap spektrum mikrob yang luas, termasuk kulat dan beberapa virus. Peptida ini dikodkan oleh gen beta-defensins; yang berubah-ubah dalam jumlah salinan. Variasi nombor salinan (CNV) beta-defensin terdapat pada populasi yang sihat. Walaupun begitu, kajian dari dekad yang lalu mendapati bahawa CNV gen beta-defensins juga menyumbang kepada beberapa penyakit radang. Oleh itu, objektif kajian ini adalah untuk mengkaji hubungan di antara variasi bilangan salinan beta-defensin dengan keadaan keradangan pada diabetes jenis 2 (T2D). Dihipotesiskan bahawa variasi bilangan salinan beta-defensin menyumbang kepada perkembangan T2D melalui pengubahsuaian dos produk daripada tindak balas imun yang menimbulkan serangan pada sel hos dan seterusnya membawa kepada keadaan keradangan pada pesakit T2D. Sampel DNA dari 146 kawalan dan 392 individu T2D diekstrak untuk kajian ini. Pengukuran bilangan salinan Beta-defensins dilakukan dengan menggunakan ujian nisbah paralog (primer PRT107A dan HSPD21) dan disahkan oleh pengukuran polimorfisma indel (primer 5DEL) dan dua analisis mikrosatelit (primer EPEV-1 dan EPEV-3). Berdasarkan analisis, variasi bilangan salinan lebih meluas dalam populasi T2D iaitu di antara 1 hingga 12 salinan; dengan salinan nombor 1, 10 dan 12 dikesan dalam kumpulan nefropati, sementara dalam populasi kawalan, nombor salinan berbeza antara 2 dan 8 salinan. Walau bagaimanapun, pengedaran nombor salinan tidak signifikan secara statistik di antara T2D dan kawalan ($p = 0.209$) dan antara mereka dengan dan tanpa nefropati dalam kalangan populasi T2D ($p = 0.522$). Walaupun begitu, jumlah sel darah putih antara individu dengan dan tanpa nefropati dari populasi T2D jauh berbeza ($p = 0.000$). Sebagai kesimpulan, lebih kajian diperlukan pada masa depan untuk meneroka lebih jauh potensi sebenar variasi bilangan salinan gen beta-defensins terhadap perkembangan nefropati pada pesakit T2D.

ACKNOWLEDGEMENTS

Alhamdulillah, finally, I managed to complete another important phase in my life. I would like to take this opportunity to express my sincere gratitude to my supervisor, Dr. Suhaili Abu Bakar for her endless encouragement and aspiring guidance that have helped me making this journey a success. Without your constructive criticism, I would not have grown into who I am today. I truly believe that one can never wish for a friendlier supervisor than you.

I would also like to thank my committee member, Prof. Dr. Patimah Ismail for her support, ideas and suggestions for the betterment of this project. I cherish the moments we spent for academic discussions as well as casual outings which I believe have strengthened our bonds.

My special appreciation goes to my best lab mates, Zahirunisa Abd Rahim, Nurul Fasihah Zulkifli, Ubaidah Naim Taraq Naem Zia, Mohd Jokha Yahya and Mohd Nazrin Shafie for being with me through this journey. May our wonderful friendship last forever. Special thanks to Encik Jokha for his kindness in sharing the valuable samples with me. Of course, I will never forget my Iranian lab mates who made my life even more colourful with your presence.

I can never thank enough the staffs of Molecular Biology and Bioinformatics Lab, Puan Noriah Idris, Puan Martini Katimin, Encik Shamsul Qamar Alias as well as Puan Nurhayati Zainal Abidin from Pharmacology Lab for providing me the help I much needed in carrying out the experiments. Finally, thank you Universiti Putra Malaysia and Ministry of Education Malaysia for funding my Master's education.

This thesis was submitted to the Senate of Universiti Putra Malaysia and has been accepted as fulfilment of the requirement for the degree of Master of Science. The members of the Supervisory Committee were as follows:

Suhaili binti Abu Bakar @ Jamaludin, PhD

Senior Lecturer
Faculty of Medicine and Health Sciences
Universiti Putra Malaysia
(Chairman)

Patimah binti Ismail, PhD

Professor
Faculty of Medicine and Health Sciences
Universiti Putra Malaysia
(Member)

BUJANG BIN KIM HUAT, PhD

Professor and Dean
School of Graduate Studies
Universiti Putra Malaysia

Date: 10 September 2015

Declaration by Members of Supervisory Committee

This is to confirm that:

- the research conducted and the writing of this thesis was under our supervision;
- supervision responsibilities as stated in the Universiti Putra Malaysia (Graduate Studies) Rules 2003 (Revision 2012-2013) are adhered to.

Signature: _____

Name of Chairman
of Supervisory
Committee:

Dr. Suhaili binti Abu Bakar @ Jamaludin

Signature: _____

Name of Member
of Supervisory
Committee:

Professor Dr. Patimah binti Ismail

TABLE OF CONTENTS

	Page
ABSTRACT	i
ABSTRAK	ii
ACKNOWLEDGEMENTS	iii
APPROVAL	iv
DECLARATION	vi
LIST OF TABLES	x
LIST OF FIGURES	xi
LIST OF APPENDICES	xiv
LIST OF ABBREVIATIONS	xv
CHAPTER	
1 INTRODUCTION	1
1.1 Background of study	1
1.2 Problem statement	2
1.3 Significance of study	2
1.4 Hypothesis	2
1.5 Objectives	2
1.5.1 General objective	2
1.5.2 Specific objectives	3
2 LITERATURE REVIEW	4
2.1 Structural variations	4
2.2 Copy number variations (CNVs)	4
2.2.1 CNV genes	5
2.2.2 Human defensins genes	7
2.2.3 Beta-defensins, its function and disease association studies	7
2.2.4 Molecular techniques for typing copy number variation of beta-defensins	10
2.3 Diabetes mellitus	12
2.3.1 T2D and activated innate immune system	14
2.3.2 Diabetic nephropathy	15
3 MATERIALS AND METHODS	16
3.1 Study population	16
3.1.1 Control and T2D individuals of Malaysian population	16
3.1.2 ECACC Human Random Control (HRC) from Caucasian origin	19
3.2 Standard methods	20
3.2.1 DNA extraction	20
3.2.2 DNA electrophoresis	20
3.2.3 Paralogue Ratio Test (PRT)	22

3.2.4	5DEL system	23
3.2.5	Triplex assay	24
3.2.6	Microsatellite analysis	25
3.3	Data analysis	26
3.3.1	Single system analysis	26
3.3.2	Maximum likelihood (ML) analysis	27
3.4	Statistical analysis	27
4	RESULTS	28
4.1	Demographic analysis	28
4.1.1	Control samples	28
4.2	Testing and quality control	29
4.2.1	Triplex assay	29
4.2.2	Microsatellite analysis	34
4.3	Establishment of control population	36
4.4	Application in case-control association study	45
4.4.1	Typing analysis in T2D population	45
4.4.2	Association study in case and control individuals	53
4.5	Beta-defensins and diabetes-related complication	54
4.5.1	Distribution comparison in T2D individuals with and without nephropathy	54
4.5.2	Beta-defensins and biomarker of inflammation	55
5	DISCUSSION	56
6	SUMMARY, CONCLUSION AND RECOMMENDATIONS FOR FUTURE RESEARCH	60
6.1	Summary	60
6.2	Conclusion	60
6.3	Study limitations and future recommendations	60
	REFERENCES	63
	APPENDICES	76
	BIODATA OF STUDENT	93
	LIST OF PUBLICATIONS	94

LIST OF TABLES

Table		Page
2.1	Examples of copy number variable genes and their association with disease susceptibility	6
3.1	PCR primer sequences used for PRT systems	22
3.2	PCR primer sequences used for indel measurement system	23
3.3	PCR primer sequences used for microsatellite analysis	25

LIST OF FIGURES

Figure		Page
2.1	Illustration of copy number variations and structural variations	5
2.2	Two repeat units of beta-defensins genes (denoted as A and B) represent copy number variations in a form of segmental duplications. Each repeat unit is comprised of seven beta-defensin genes which are variable in copy number	8
2.3	Beta-defensins copy number distribution in seven HapMap populations that have been genotyped	8
2.4	Illustration showing the comparison between T1D and T2D with normal blood glucose condition	12
2.5	Major diabetes complications	13
3.1	A schematic diagram for this case-control study	17
3.2	Electropherogram as recorded by Peak Scanner™ for a 4-copy sample typed by Triplex assay. Test and reference peaks for PRT systems for FAM-labelled products are shown by arrows. For HEX-labelled 5DEL system, ratio of each peak to the smallest peak (1:1) was taken and multiplied by a factor of 2 to reflect copy number of 4 as typed by PRT systems	24
3.3	Electropherogram as recorded by Peak Scanner™ for 4-copy sample typed by microsatellite analysis. Ratio of each true peak to the smallest peak (1:2:1) was taken, which resulted in a total copy number of 4 as typed by PRT systems	26
4.1	Ethnic distribution for control individuals	28
4.2	Ethnic distribution for T2D individuals	29
4.3	Amplification products from duplex PCR reaction of PRT107A and HSPD21 for control (85, 86, 87, 88 and 89) and ECACC (C27) sample resulted in two distinct bands	30
4.4	The presence of indel polymorphism in control (N and 213) and T2D (D3 and D26) samples after amplification by 5DEL system as displayed by the single bands	31
4.5	Electropherogram recorded by Peak Scanner™ for amplification products of Triplex assay. Four references samples with known copy	

	number were used: (a) C71 (n=3), (b) C5 (n=4), (c) C40 (n=5), (d) C96 (n=6)	32
4.6	Derivation of linear regression from C71, C5, C40 and C96 which were used in copy number inferring of unknown samples for (a) PRT107A and (b) HSPD21	33
4.7	Derivation of linear regression from C14, C45 and C65 which were used in copy number inferring of unknown samples for (a) PRT107A and (b) HSPD21	34
4.8	The presence of microsatellite alleles after amplification by EPEV-1 and EPEV-3 displayed as multiple bands in certain samples due to small differences in allele sizes	35
4.9	Electropherogram recorded by Peak Scanner™ for microsatellite alleles after amplification by EPEV-1 and EPEV-3. Four reference samples with known copy number were used: (a) C71 (n=3), (b) C5 (n=4), (c) C40 (n=5), (d) C96 (n=6)	36
4.10	Scatterplot of unrounded copy number in control individuals by PRT107A and HSPD21. The x- and y-axis indicate the copy number by PRT systems	37
4.11	Histogram of unrounded copy number in control individuals by PRT systems: (a) PRT107A (b) HSPD21 (c) combination of both systems. The dotted blue lines are included to help distinguish each copy number class	38
4.12	Histogram of integer copy number in control individuals by PRT107A and HSPD21	39
4.13	Scatterplot of unrounded copy number by PRT107A and HSPD21 in control individuals after linear adjustment was applied in PRT107A typing. The x- and y-axis indicate the copy number by PRT systems	40
4.14	Histogram of unrounded copy number in control individuals: (a) before and after PRT107A adjustment, (b) adjusted PRT107A and HSPD21. The dotted blue lines are included to help distinguish each copy number class	41
4.15	Histogram of integer copy number in control individuals by adjusted PRT107A and HSPD21	42
4.16	Histogram of integer copy number in control individuals by using single system analysis of Triplex assay	42

4.17	(a) Histogram of integer copy number in control individuals by using ML. (b) Comparison of copy number distribution between single system and ML	43
4.18	Histograms of integer copy number between ECACC and control individuals. Two approaches in copy number analysis were carried out: (a) single system (b) ML	44
4.19	Histogram of integer copy number across three major ethnics of control individuals	45
4.21	Histograms of unrounded copy number in T2D individuals by using (a) PRT107A, (b) HSPD21, (c) both PRT systems. The dotted blue lines are included to help distinguish each copy number class	47
4.22	Histogram of integer copy number in T2D individuals by both PRT systems	48
4.23	Scatterplot of unrounded copy number in T2D individuals by both PRTs after linear adjustment has been applied to PRT107A typing. The x- and y-axis indicate the copy number by PRT systems	49
4.24	Histograms of unrounded copy number in T2D individuals. (a) before and after PRT107A adjustment, (b) adjusted PRT107A and HSPD21. The dotted blue lines are included to help distinguish each copy number class	50
4.25	Histogram of integer copy number in T2D individuals by adjusted PRT107A and HSPD21	51
4.26	Histogram of integer copy number in T2D individuals by using single system analysis of Triplex assay	51
4.27	(a) Histogram of integer copy number in T2D individuals by using ML. (b) Comparison of copy number distribution between single system and ML	52
4.28	Histogram of integer copy number across three major ethnics of T2D individuals	53
4.29	Histogram of integer copy number distribution in control and T2D individuals	54
4.30	Histogram showed copy number distribution between T2D individuals with and without nephropathy (neph = nephropathy)	55

LIST OF APPENDICES

Appendix		Page
A	Ethical Approval	76
B	Respondent Information Sheet and Consent Form	78
C	Case Report Form	85
D	ECACC HRC-1 and HRC-2 Product Data Sheets	88
E	T2D Samples with Copy Number Inferred by Triplex Assay and Microsatellite Analysis	90
F	Sample of 1 Copy Beta-Defensins Gene	91
G	Examples of Overestimated Copy Number by PRT107A	92

LIST OF ABBREVIATIONS

AMP	Antimicrobial peptide
ANCA	Antineutrophil cytoplasmic antibody
ANOVA	Analysis of Variance
<i>APP</i>	Amyloid beta (A4) precursor protein
array-CGH	Array-comparative genomic hybridization
BAC	Bacterial artificial chromosome
<i>C4</i>	Complement component C4
<i>CCL3LI</i>	Chemokine (C-C) motif ligand 3 like 1
CCR2	C-C chemokine receptor type 2
CNVs	Copy number variations
CRP	C-reactive protein
<i>DEFB</i>	Beta-defensin
DNA	Deoxyribonucleic acid
EBV	Epstein Barr virus
ECACC	European Collection of Cell Cultures
EDTA	Ethylenediaminetetraacetic acid
ELISA	Enzyme-linked immunosorbent assay
<i>FCGR3B</i>	Fc fragment of IgG, low affinity IIIb, receptor
<i>GSK3β</i>	Glycogen synthase kinase 3 beta
GWAS	Genome-wide association study
hBD	Human beta-defensin
HIV	Human immunodeficiency virus
HRC	Human random control
IDF	International Diabetes Federation

IL-1	Interleukin-1
IL-6	Interleukin-6
Indel	Insertion/deletion
MAPH	Multiplex amplifiable probe hybridization
MBL	Mannose-binding lectin
ML	Maximum likelihood
MLPA	Multiplex ligation-dependent probe amplification
mRNA	Messenger RNA
NCBI	National Center for Biotechnology Information
NHMS	National Health and Morbidity Survey
PCA	Principal Component Analysis
NMRR	National Medical Research Register
PCR	Polymerase chain reaction
<i>PLP1</i>	Proteolipid protein 1
PRR	pattern recognition receptors
<i>PRSSI</i>	Protease, Serine 1
PRT	Paralogue ratio test
QMPSF	Quantitative multiplex PCR of short fluorescent fragment
q-PCR	Real-time PCR
rBD	Rat beta-defensin
REDVR	Restriction enzyme digest variant ratio
RFLP	Restriction fragment length polymorphism
RIA	Radioimmunoassay
SLE	Systemic lupus erythematosus
<i>SNCA</i>	Synuclein, alpha (non A4 component of amyloid)

SNP	Single nucleotide polymorphism
<i>SPAG11</i>	Sperm-associated antigen 11
STR	Short tandem repeat
T1D	Type 1 diabetes
T2D	Type 2 diabetes
TNF- α	Tumour necrosis factor- α
<i>TSPAN8</i>	Tetraspanin 8
UCSC	University of California, Santa Cruz
<i>UGT2B17</i>	UDP-glucuronosyltransferase 2B17
VNTRs	Variable number of tandem repeats
WBC	White blood cells
WTCCC	Wellcome Trust Case Control Consortium

CHAPTER 1

INTRODUCTION

1.1 Background of study

Over the past decade, scientists have started to appreciate the contribution of structural genetic variations to human diseases. One of the most extensively studied structural variations is Copy Number Variation (CNV). Since then, increasing number of loci containing functional genes has been described to be variable in copy number (Iafrate et al., 2004; Sebat et al., 2004; Tuzun et al., 2005; McCarroll and Altshuler, 2007). This genetic variation affects the humans through dosage-dependent manner, thus increasing or decreasing the susceptibility towards certain diseases (Wain et al., 2009). Chromosome band 8p23.1 contains immune-related, copy number variable gene known as beta-defensins which encode important antimicrobial peptide of the body (Schutte et al., 2002). This predominant peptide is known for its ability to kill various pathogens including some fungi and viruses by forming pores on the membrane, acknowledging its important role in innate immune defence (Ganz, 2003). Moreover, beta-defensins also engage to the adaptive immune system through its cytokine-like properties, attracting cells of the immune system towards infection or inflammation site (Rohrl et al., 2010). Dysregulation of body's beta-defensin peptides increased susceptibility to a number of diseases such as human immunodeficiency virus (HIV) infection, psoriasis, systemic lupus erythematosus (SLE) and anti-neutrophil cytoplasmic antibody (ANCA)-associated small vasculitis (Hollox et al., 2008a; Hardwick et al., 2012; Zhou et al., 2012). Recent in vivo study in diabetic rats found low rodent beta-defensin-1 (rBD)-1 level in the kidney compared to the controls, indicating an inflammatory reaction (Froy et al., 2007; Barnea et al., 2008). This finding is parallel to the nature of its human orthologue known as hBD-1 (human beta-defensin-1); encoded by *DEFB1* gene that is constitutively expressed in the kidney. Although *DEFB1* is map outside the beta-defensins repeat unit (Hollox et al., 2008d), it gives a hint of how significant an inflammatory effect can be resulted in relation to this antimicrobial peptide. Thus, a more profound consequence is speculated if association exist with other beta-defensins of variable repeats through alteration in product dosage. Nevertheless, the reports concerning this locus are still lacking. Hence, further investigation of the effect of beta-defensins copy number variable gene to the development of T2D is crucial to elucidate the role played by copy number variations in complex metabolic disease. Therefore, in this study, copy number of beta-defensins is quantified by using Paralogue Ratio Test (PRT) which is a comparative PCR technique. Validation of the results was carried out by using insertion-deletion (indel) polymorphism measurement and microsatellite analysis. In most diagnostic laboratory, white blood cell (WBC) count which acts as a parameter was utilised in this study to assess the inflammatory status of the patients. Thus, the relationship between this biological marker and beta-defensins is investigated from the genetics point of view.

1.2 Problem statement

The contribution of copy number variation towards diseases mostly involves genes that mediate the immune system; thus, predisposing humans to either infectious or inflammatory diseases, with respect to the gene dosage (Wain et al., 2009). Beta-defensins gene has an extensive variation and this variation has been demonstrated in healthy individuals from other populations (Hollox et al., 2003; Hollox, 2008d). Research in distinguishing between non-threatening and disease-causing variants involving copy number variation is still in the early stages (Zhang et al., 2009). The hurdles faced in understanding copy number variations increases when it involves complex diseases, as seen in T2D. Therefore, this study was carried out with emphasis on beta-defensins copy number variable gene due to limited knowledge in Malaysian context to serve as a reference.

1.3 Significance of study

The findings generated from this study will remarkably contribute particular data and knowledge for beta-defensins gene distribution in Malaysian context for research concerning copy number variations. In addition, this knowledge can be utilised by other researchers to develop personalised medicine for treating T2D or any diseases related to beta-defensins imbalances more effectively.

1.4 Hypothesis

It is hypothesised that there will be a different copy number distribution of beta-defensins between Malaysian and Caucasian control population. Besides that, copy number distribution between major ethnics of Malaysian individuals is speculated to show significant differences. Variation in copy number distribution could modify immune products dosage, whereby indirect attacks on the host cells could be exerted. This mechanism will introduce inflammation in T2D patients.

1.5 Objectives

1.5.1 General objective

To investigate the relationship between copy number variation of beta-defensins with inflammation found in T2D.

1.5.2 Specific objectives

- 1) To quantify beta-defensins copy number in Malaysian controls and compare it with established copy number distribution in Caucasian individuals as the reference population.
- 2) To quantify beta-defensins copy number in T2D individuals and compare it with copy number distribution in Malaysian control population.
- 3) To investigate the risk of developing T2D between major ethnics of Malaysian population with respect to variable copies of beta-defensins gene.
- 4) To determine the relationship between beta-defensins copy number and WBC count in T2D population.

REFERENCES

- Abu Bakar, S., Hollox, E. J., and Armour, J. A. (2009). Allelic recombination between distinct genomic locations generates copy number diversity in human beta-defensins. *Proceedings of the National Academy of Sciences of the United States of America*, 106(3), 853-858. doi: 10.1073/pnas.0809073106
- Aitman, T. J., Dong, R., Vyse, T. J., Norsworthy, P. J., Johnson, M. D., Smith, J., Mangion, J., Robertson-Lowe, C., Marshall, A. J., and Petretto, E. (2006). Copy number polymorphism in *Fcgr3* predisposes to glomerulonephritis in rats and humans. *Nature*, 439(7078), 851-855.
- Aldhous, M. C., Abu Bakar, S., Prescott, N. J., Palla, R., Soo, K., Mansfield, J. C., Mathew, C. G., Satsangi, J., and Armour, J. A. (2010). Measurement methods and accuracy in copy number variation: failure to replicate associations of beta-defensin copy number with Crohn's disease. *Human Molecular Genetics*, 19(24), 4930-4938. doi: 10.1093/hmg/ddq411
- Al-Rubeaan, K., Youssef, A. M., Subhani, S. N., Ahmad, N. A., Al-Sharqawi, A. H., Al-Mutlaq, H. M., David, S. K., and AlNaqeb, D. (2014). Diabetic Nephropathy and Its Risk Factors in a Society with a Type 2 Diabetes Epidemic: A Saudi National Diabetes Registry-Based Study. *PLoS One*, 9(2), e88956.
- American Diabetes Association (2000). Diabetic nephropathy. *Diabetes Care*, 23, S69.
- Armour, J. A. L., Sismani, C., Patsalis, P. C., and Cross, G. (2000). Measurement of locus copy number by hybridisation with amplifiable probes. *Nucleic Acids Research*, 28(2), 605-609. doi: 10.1093/nar/28.2.605
- Armour, J. A., Palla, R., Zeeuwen, P. L., den Heijer, M., Schalkwijk, J., and Hollox, E. J. (2007). Accurate, high-throughput typing of copy number variation using paralogue ratios from dispersed repeats. *Nucleic Acids Research*, 35(3), e19. doi: 10.1093/nar/gkl1089
- Bailey, J. A., Gu, Z., Clark, R. A., Reinert, K., Samonte, R. V., Schwartz, S., Adams, M. D., Myers, E. W., Li, P. W., and Eichler, E. E. (2002). Recent segmental duplications in the human genome. *Science*, 297(5583), 1003-1007. doi: 10.1126/science.1072047
- Barnea, M., Madar, Z., and Froy, O. (2008). Glucose and insulin are needed for optimal defensin expression in human cell lines. *Biochemical and Biophysical Research Communications*, 367(2), 452-456. doi: http://dx.doi.org/10.1016/j.bbrc.2007.12.158
- Bentley, R. W., Pearson, J., Gearry, R. B., Barclay, M. L., McKinney, C., Merriman, T. R., and Roberts, R. L. (2010). Association of higher DEFB4 genomic copy number with Crohn's disease. *The American Journal of Gastroenterology*, 105(2), 354-359. doi: 10.1038/ajg.2009.582

- BoonPeng, H., and Yusoff, K. (2013). The utility of copy number variation (CNV) in studies of hypertension-related left ventricular hypertrophy (LVH): rationale, potential and challenges. *Molecular cytogenetics*, 6(1), 8.
- Buckland, P. R. (2003). Polymorphically duplicated genes: their relevance to phenotypic variation in humans. *Annals of Medicine*, 35(5), 308-315.
- Cantsilieris, S., Baird, P. N., and White, S. J. (2012). Molecular methods for genotyping complex copy number polymorphisms. *Genomics*. doi: 10.1016/j.ygeno.2012.10.004
- Carpenter, D., Walker, S., Prescott, N., Schalkwijk, J., and Armour, J. A. (2011). Accuracy and differential bias in copy number measurement of CCL3L1 in association studies with three auto-immune disorders. *BMC Genomics*, 12, 418. doi: 10.1186/1471-2164-12-418
- Cauchi, S., Choquet, H., Gutiérrez- Aguilar, R., Capel, F., Grau, K., Proença, C., Dina, C., Duval, A., Balkau, B., and Marre, M. (2008). Effects of TCF7L2 polymorphisms on obesity in European populations. *Obesity*, 16(2), 476-482.
- Chen, Q., Book, M., Fang, X., Hoelt, A., and Stuber, F. (2006). Screening of copy number polymorphisms in human β -defensin genes using modified real-time quantitative PCR. *Journal of Immunological Methods*, 308(1-2), 231-240. doi: <http://dx.doi.org/10.1016/j.jim.2005.11.001>
- Chow, B. T., Soto, M., Lo, B. L., Crosby, D. C., and Camerini, D. (2012). Antibacterial Activity of Four Human Beta-Defensins: HBD-19, HBD-23, HBD-27, and HBD-29. *Polymers*, 4(4), 747-758. doi: 10.3390/polym4010747
- Chung, F. M., Tsai, J. C., Chang, D. M., Shin, S. J., and Lee, Y. J. (2005). Peripheral total and differential leukocyte count in diabetic nephropathy: the relationship of plasma leptin to leukocytosis. *Diabetes Care*, 28(7), 1710-1717.
- Cole, A. M., Hong, T., Boo, L. M., Nguyen, T., Zhao, C., Bristol, G., Zack, J. A., Waring, A. J., Yang, O. O., and Lehrer, R. I. (2002). Retrocyclin: a primate peptide that protects cells from infection by T- and M-tropic strains of HIV-1. *Proceedings of the National Academy of Sciences of the United States of America*, 99(4), 1813-1818. doi: 10.1073/pnas.052706399
- de Smith, A. J., Walters, R. G., Froguel, P., and Blakemore, A. I. (2008). Human genes involved in copy number variation: mechanisms of origin, functional effects and implications for disease. *Cytogenetics and Genome Research*, 123(1-4), 17-26. doi: 10.1159/000184688
- Doria, A., Patti, M.-E., and Kahn, C. R. (2008). The emerging genetic architecture of type 2 diabetes. *Cell metabolism*, 8(3), 186-200.

- Fanciulli, M., Norsworthy, P. J., Petretto, E., Dong, R., Harper, L., Kamesh, L., Heward, J. M., Gough, S. C., de Smith, A., Blakemore, A. I., Froguel, P., Owen, C. J., Pearce, S. H., Teixeira, L., Guillevin, L., Graham, D. S., Pusey, C. D., Cook, H. T., Vyse, T. J., and Aitman, T. J. (2007). FCGR3B copy number variation is associated with susceptibility to systemic, but not organ-specific, autoimmunity. *Nature Genetics*, 39(6), 721-723. doi: 10.1038/ng2046
- Farrer, M., Kachergus, J., Forno, L., Lincoln, S., Wang, D. S., Hulihan, M., Maraganore, D., Gwinn-Hardy, K., Wszolek, Z., Dickson, D., and Langston, J. W. (2004). Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. *Annals of Neurology*, 55(2), 174-179. doi: 10.1002/ana.10846
- Feisul, I. M. "Current burden of diabetes in Malaysia," in Proceedings of the 1st National Institutes of Health (NIH) Scientific Meeting, Selangor, Malaysia, June 2012.
- Fellermann, K., Stange, D. E., Schaeffeler, E., Schmalzl, H., Wehkamp, J., Bevins, C. L., Reinisch, W., Teml, A., Schwab, M., Lichter, P., Radlwimmer, B., and Stange, E. F. (2006). A chromosome 8 gene-cluster polymorphism with low human beta-defensin 2 gene copy number predisposes to Crohn disease of the colon. *The American Journal of Human Genetics*, 79(3), 439-448. doi: 10.1086/505915
- Feng, Z., Dubyak, G. R., Lederman, M. M., and Weinberg, A. (2006). Cutting edge: human beta defensin 3--a novel antagonist of the HIV-1 coreceptor CXCR4. *The Journal of Immunology*, 177(2), 782-786.
- Fernandez-Jimenez, N., Castellanos-Rubio, A., Plaza-Izurieta, L., Gutierrez, G., Irastorza, I., Castano, L., Vitoria, J. C., and Bilbao, J. R. (2011). Accuracy in copy number calling by qPCR and PRT: a matter of DNA. *PLoS One*, 6(12), e28910. doi: 10.1371/journal.pone.0028910
- Fernandez-Real, J. M. (2006). Genetic predispositions to low-grade inflammation and type 2 diabetes. *Diabetes Technology and Therapeutics*, 8(1), 55-66. doi: 10.1089/dia.2006.8.55
- Fernandez-Real, J. M., and Pickup, J. C. (2008). Innate immunity, insulin resistance and type 2 diabetes. *Trends in Endocrinology and Metabolism*, 19(1), 10-16. doi: 10.1016/j.tem.2007.10.004
- Fernando, M. M. A., Boteva, L., Morris, D. L., Zhou, B., Wu, Y. L., Lokki, M.-L., Yu, C. Y., Rioux, J. D., Hollox, E. J., and Vyse, T. J. (2010). Assessment of complement C4 gene copy number using the paralog ratio test. *Human Mutation*, 31(7), 866-874. doi: 10.1002/humu.21259
- Feuk, L., Carson, A. R., and Scherer, S. W. (2006). Structural variation in the human genome. *Nature Reviews Genetics*, 7(2), 85-97. doi: 10.1038/nrg1767

- Florez, J. C., Jablonski, K. A., Bayley, N., Pollin, T. I., de Bakker, P. I., Shuldiner, A. R., Knowler, W. C., Nathan, D. M., and Altshuler, D. (2006). TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. *New England Journal of Medicine*, 355(3), 241-250.
- Fode, P., Stegger, M., and Andersen, P. S. (2011). Human beta-defensin 3 (DEFB103) and its influence on *Staphylococcus aureus* nasal carriage. *International Journal of Infectious Diseases*, 15(6), e388-394. doi: 10.1016/j.ijid.2011.02.003
- Foggensteiner, L., Mulroy, S., and Firth, J. (2001). Management of diabetic nephropathy. *Journal of the Royal Society of Medicine*, 94(5), 210-217.
- Freedman, B. I., Bostrom, M., Daeihagh, P., and Bowden, D. W. (2007). Genetic Factors in Diabetic Nephropathy. *Clinical Journal of the American Society of Nephrology*, 2(6), 1306-1316. doi: 10.2215/cjn.02560607
- Freeman, J. L., Perry, G. H., Feuk, L., Redon, R., McCarroll, S. A., Altshuler, D. M., Aburatani, H., Jones, K. W., Tyler-Smith, C., Hurles, M. E., Carter, N. P., Scherer, S. W., and Lee, C. (2006). Copy number variation: new insights in genome diversity. *Genome Research*, 16(8), 949-961. doi: 10.1101/gr.3677206
- Froy, O., Hananel, A., Chapnik, N., and Madar, Z. (2007). Differential effect of insulin treatment on decreased levels of beta-defensins and Toll-like receptors in diabetic rats. *Molecular Immunology*, 44(5), 796-802. doi: <http://dx.doi.org/10.1016/j.molimm.2006.04.009>
- Ganz, T. (2003). Defensins: antimicrobial peptides of innate immunity. *Nature Reviews Immunology*, 3(9), 710-720. doi: 10.1038/nri1180
- Gonzalez, E., Kulkarni, H., Bolivar, H., Mangano, A., Sanchez, R., Catano, G., Nibbs, R. J., Freedman, B. I., Quinones, M. P., Bamshad, M. J., Murthy, K. K., Rovin, B. H., Bradley, W., Clark, R. A., Anderson, S. A., O'Connell, R. J., Agan, B. K., Ahuja, S. S., Bologna, R., Sen, L., Dolan, M. J., and Ahuja, S. K. (2005). The Influence of CCL3L1 Gene-Containing Segmental Duplications on HIV-1/AIDS Susceptibility. *Science*, 307(5714), 1434-1440. doi: 10.1126/science.1101160
- Groop, L., and Pociot, F. (2014). Genetics of diabetes – Are we missing the genes or the disease? *Molecular and Cellular Endocrinology*, 382(1), 726-739. doi: <http://dx.doi.org/10.1016/j.mce.2013.04.002>
- Groth, M., Szafranski, K., Taudien, S., Huse, K., Mueller, O., Rosenstiel, P., Nygren, A. O. H., Schreiber, S., Birkenmeier, G., and Platzer, M. (2008). High-resolution mapping of the 8p23.1 beta-defensin cluster reveals strictly concordant copy number variation of all genes. *Human Mutation*, 29(10), 1247-1254. doi: 10.1002/humu.20751

- Hamid, Y. H., Rose, C. S., Urhammer, S. A., Glumer, C., Nolsoe, R., Kristiansen, O. P., Mandrup-Poulsen, T., Borch-Johnsen, K., Jorgensen, T., Hansen, T., and Pedersen, O. (2005). Variations of the interleukin-6 promoter are associated with features of the metabolic syndrome in Caucasian Danes. *Diabetologia*, *48*(2), 251-260. doi: 10.1007/s00125-004-1623-0
- Haraksingh, R. R., and Snyder, M. P. (2013). Impacts of Variation in the Human Genome on Gene Regulation. *Journal of Molecular Biology*, *425*(21), 3970-3977. doi: <http://dx.doi.org/10.1016/j.jmb.2013.07.015>
- Hardwick, R. J., Amogne, W., Mugusi, S., Yimer, G., Ngaimisi, E., Habtewold, A., Minzi, O., Makonnen, E., Janabi, M., Machado, L. R., Viskaduraki, M., Mugusi, F., Aderaye, G., Lindquist, L., Hollox, E. J., and Aklillu, E. (2012). beta-defensin genomic copy number is associated with HIV load and immune reconstitution in sub-saharan Africans. *The Journal of Infectious Diseases*, *206*(7), 1012-1019. doi: 10.1093/infdis/jis448
- Hollox, E. J. (2008d). Copy number variation of beta-defensins and relevance to disease. *Cytogenetic and Genome Research*, *123*(1-4), 148-155. doi: 10.1159/000184702
- Hollox, E. J., and Armour, J. A. (2008b). Directional and balancing selection in human beta-defensins. *BMC Evolutionary Biology*, *8*, 113. doi: 10.1186/1471-2148-8-113
- Hollox, E. J., Armour, J. A., and Barber, J. C. (2003). Extensive normal copy number variation of a beta-defensin antimicrobial-gene cluster. *The American Journal of Human Genetics*, *73*(3), 591-600. doi: 10.1086/378157
- Hollox, E. J., Barber, J. C. K., Brookes, A. J., and Armour, J. A. L. (2008c). Defensins and the dynamic genome: What we can learn from structural variation at human chromosome band 8p23.1. *Genome Research*, *18*(11), 1686-1697. doi: 10.1101/gr.080945.108
- Hollox, E. J., Davies, J., Griesenbach, U., Burgess, J., Alton, E. W., and Armour, J. A. (2005). Beta-defensin genomic copy number is not a modifier locus for cystic fibrosis. *Journal of Negative Results in Biomedicine*, *4*, 9. doi: 10.1186/1477-5751-4-9
- Hollox, E. J., Detering, J. C., and Dehnugara, T. (2009). An integrated approach for measuring copy number variation at the FCGR3 (CD16) locus. *Human Mutation*, *30*(3), 477-484. doi: 10.1002/humu.20911
- Hollox, E. J., Huffmeier, U., Zeeuwen, P. L., Palla, R., Lascorz, J., Rodijk-Olthuis, D., van de Kerkhof, P. C., Traupe, H., de Jongh, G., den Heijer, M., Reis, A., Armour, J. A., and Schalkwijk, J. (2008a). Psoriasis is associated with increased beta-defensin genomic copy number. *Nature Genetics*, *40*(1), 23-25. doi: 10.1038/ng.2007.48

- Hunter, P. (2012). The inflammation theory of disease: The growing realization that chronic inflammation is crucial in many diseases opens new avenues for treatment. *EMBO Reports*, *13*(11), 968-970. doi: 10.1038/embor.2012.142
- Iafraite, A. J., Feuk, L., Rivera, M. N., Listewnik, M. L., Donahoe, P. K., Qi, Y., Scherer, S. W., and Lee, C. (2004). Detection of large-scale variation in the human genome. *Nature Genetics*, *36*(9), 949-951. doi: 10.1038/ng1416
- International Diabetes Federation (2009). IDF Diabetes Atlas - 4th edition.–Brussels, Belgium.
- International Diabetes Federation (2013). IDF Diabetes Atlas - 6th edition.–Brussels, Belgium.
- Jacquier, V., Estelle, J., Schmaltz-Panneau, B., Lecardonnel, J., Moroldo, M., Lemonnier, G., Turner-Maier, J., Duranthon, V., Oswald, I., Gidenne, T., and Rogel-Gaillard, C. (2015). Genome-wide immunity studies in the rabbit: transcriptome variations in peripheral blood mononuclear cells after in vitro stimulation by LPS or PMA-Ionomycin. *BMC Genomics*, *16*(1), 26.
- Jones, E. A., Kananurak, A., Bevins, C. L., Hollox, E. J., and Bakaletz, L. O. (2014). Copy number variation of the beta defensin gene cluster on chromosome 8p influences the bacterial microbiota within the nasopharynx of otitis-prone children. *PLoS One*, *9*(5), e98269. doi: 10.1371/journal.pone.0098269
- Kaprio, J., Tuomilehto, J., Koskenvuo, M., Romanov, K., Reunanen, A., Eriksson, J., Stengard, J., and Kesaniemi, Y. A. (1992). Concordance for type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetes mellitus in a population-based cohort of twins in Finland. *Diabetologia*, *35*(11), 1060-1067.
- Khan, F., Carpenter, D., Mitchell, L., Mansouri, O., Black, H., Tyson, J., and Armour, J. (2013). Accurate measurement of gene copy number for human alpha-defensin DEFA1A3. *BMC Genomics*, *14*(1), 719.
- Kim, S. H., Ma, X., Weremowicz, S., Ercolino, T., Powers, C., Mlynarski, W., Bashan, K. A., Warram, J. H., Mychaleckyj, J., Rich, S. S., Krolewski, A. S., and Doria, A. (2004). Identification of a locus for maturity-onset diabetes of the young on chromosome 8p23. *Diabetes*, *53*(5), 1375-1384.
- King, G. L. (2008). The role of inflammatory cytokines in diabetes and its complications. *Journal of Periodontology*, *79*(8 Suppl), 1527-1534. doi: 10.1902/jop.2008.080246
- Kitamura, A., Hasegawa, G., Obayashi, H., Kamiuchi, K., Ishii, M., Yano, M., Tanaka, T., Yamaguchi, M., Shigeta, H., Ogata, M., Nakamura, N., and Yoshikawa, T. (2002). Interleukin-6 polymorphism (−634C/G) in the promotor region and the progression of diabetic nephropathy in Type 2 diabetes. *Diabetic Medicine*, *19*(12), 1000-1005. doi: 10.1046/j.1464-5491.2002.00844.x

- Klein, R., Klein, B. E., Moss, S. E., Davis, M. D., and DeMets, D. L. (1984). The Wisconsin epidemiologic study of diabetic retinopathy: IV. Diabetic macular edema. *Ophthalmology*, *91*(12), 1464-1474.
- Klotman, M. E., and Chang, T. L. (2006). Defensins in innate antiviral immunity. [10.1038/nri1860]. *Nature Reviews Immunology*, *6*(6), 447-456.
- Kolb, H., and Mandrup-Poulsen, T. (2005). An immune origin of type 2 diabetes? *Diabetologia*, *48*(6), 1038-1050. doi: 10.1007/s00125-005-1764-9
- Kolek, M. J., Carlquist, J. F., Muhlestein, J. B., Whiting, B. M., Horne, B. D., Bair, T. L., and Anderson, J. L. (2004). Toll-like receptor 4 gene Asp299Gly polymorphism is associated with reductions in vascular inflammation, angiographic coronary artery disease, and clinical diabetes. *American Heart Journal*, *148*(6), 1034-1040. doi: 10.1016/j.ahj.2004.05.049
- Kung, W.-J., Lin, C.-C., Liu, S.-H., and Chaung, H.-C. (2010). Association of interleukin-10 polymorphisms with cytokines in type 2 diabetic nephropathy. *Diabetes Technology and Therapeutics*, *12*(10), 809-813.
- Lachman, H. M., Pedrosa, E., Petruolo, O. A., Cockerham, M., Papolos, A., Novak, T., Papolos, D. F., and Stopkova, P. (2007). Increase in GSK3 β gene copy number variation in bipolar disorder. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics*, *144*(3), 259-265.
- Le Maréchal, C., Masson, E., Chen, J.-M., Morel, F., Ruzsniwski, P., Levy, P., and Férec, C. (2006). Hereditary pancreatitis caused by triplication of the trypsinogen locus. *Nature Genetics*, *38*(12), 1372-1374.
- Lee, J. A., Madrid, R. E., Sperle, K., Ritterson, C. M., Hobson, G. M., Garbern, J., Lupski, J. R., and Inoue, K. (2006). Spastic paraplegia type 2 associated with axonal neuropathy and apparent PLP1 position effect. *Annals of Neurology*, *59*(2), 398-403.
- Lee, S.-H., Lee, T. W., Ihm, C.-G., Kim, M. J., Woo, J.-T., and Chung, J.-H. (2005). Genetics of diabetic nephropathy in type 2 DM: candidate gene analysis for the pathogenic role of inflammation. *Nephrology*, *10*, S32-S36. doi: 10.1111/j.1440-1797.2005.00454.x
- Letchuman, G., Wan Nazaimoon, W., Wan Mohamad, W., Chandran, L., Tee, G., Jamaiah, H., Isa, M., Zanariah, H., Fatanah, I., and Ahmad Faudzi, Y. (2010). Prevalence of diabetes in the Malaysian national health morbidity survey III 2006. *Medical Journal of Malaysia*, *65*(3), 180-186.
- Licastro, F., Candore, G., Lio, D., Porcellini, E., Colonna-Romano, G., Franceschi, C., and Caruso, C. (2005). Innate immunity and inflammation in ageing: a key for understanding age-related diseases. *Immunity and Ageing*, *2*, 8. doi: 10.1186/1742-4933-2-8

- Linzmeier, R. M., and Ganz, T. (2005). Human defensin gene copy number polymorphisms: comprehensive analysis of independent variation in alpha- and beta-defensin regions at 8p22-p23. *Genomics*, 86(4), 423-430. doi: 10.1016/j.ygeno.2005.06.003
- Liu, A. Y., Destoumieux, D., Wong, A. V., Park, C. H., Valore, E. V., Liu, L., and Ganz, T. (2002). Human beta-defensin-2 production in keratinocytes is regulated by interleukin-1, bacteria, and the state of differentiation. *Journal of Investigative Dermatology*, 118(2), 275-281. doi: 10.1046/j.0022-202x.2001.01651.x
- Liu, Y. H., Wan, L., Chang, C. T., Liao, W. L., Chen, W. C., Tsai, Y., Tsai, C. H., and Tsai, F. J. (2011). Association between copy number variation of complement component C4 and Graves' disease. *Journal of Biomedical Science*, 18, 71. doi: 10.1186/1423-0127-18-71
- Loughrey, B. V., Maxwell, A. P., Fogarty, D. G., Middleton, D., Harron, J. C., Patterson, C. C., Darke, C., and Savage, D. A. (1998). An interleukin 1b allele, which correlates with a high secretor phenotype, is associated with diabetic nephropathy. *Cytokine*, 10(12), 984-988. doi: <http://dx.doi.org/10.1006/cyto.1998.0388>
- Lwanga, S. K., and Lemeshow, S. (1991). Sample size determination in health studies: a practical manual: World Health Organization.
- Madsen, H. O., Garred, P., Thiel, S., Kurtzhals, J. A., Lamm, L. U., Ryder, L. P., and Svejgaard, A. (1995). Interplay between promoter and structural gene variants control basal serum level of mannan-binding protein. *The Journal of Immunology*, 155(6), 3013-3020.
- Mamtani, M., Rovin, B., Brey, R., Camargo, J. F., Kulkarni, H., Herrera, M., Correa, P., Holliday, S., Anaya, J.-M., and Ahuja, S. K. (2007). CCL3L1 gene-containing segmental duplications and polymorphisms in CCR5 affect risk of systemic lupus erythematosus. *Annals of The Rheumatic Diseases*.
- McKinney, C., Merriman, M. E., Chapman, P. T., Gow, P. J., Harrison, A. A., Highton, J., Jones, P. B., McLean, L., O'Donnell, J. L., and Pokorny, V. (2008). Evidence for an influence of chemokine ligand 3-like 1 (CCL3L1) gene copy number on susceptibility to rheumatoid arthritis. *Annals of the rheumatic diseases*, 67(3), 409-413.
- Molokhia, M., Fanciulli, M., Petretto, E., Patrick, A. L., McKeigue, P., Roberts, A. L., Vyse, T. J., and Aitman, T. J. (2011). FCGR3B copy number variation is associated with systemic lupus erythematosus risk in Afro-Caribbeans. *Rheumatology (Oxford)*, 50(7), 1206-1210. doi: 10.1093/rheumatology/keq456
- Nakajima, T., Kaur, G., Mehra, N., and Kimura, A. (2008). HIV-1/AIDS susceptibility and copy number variation in CCL3L1, a gene encoding a natural ligand for HIV-1 co-receptor CCR5. *Cytogenetic and Genome Research*, 123(1-4), 156-160. doi: 10.1159/000184703

- Nazir, N., Siddiqui, K., Al-Qasim, S., and Al-Naqeb, D. (2014). Meta-analysis of diabetic nephropathy associated genetic variants in inflammation and angiogenesis involved in different biochemical pathways. *BMC Medical Genetics*, *15*(1), 103. doi: 10.1186/s12881-014-0103-8
- Nemeth, B. C., Varkonyi, T., Somogyvari, F., Lengyel, C., Fehertemplomi, K., Nyiraty, S., Kempler, P., and Mandi, Y. (2014). Relevance of alpha-defensins (HNPI-3) and defensin beta-1 in diabetes. *World Journal of Gastroenterology*, *20*(27), 9128-9137. doi: 10.3748/wjg.v20.i27.9128
- Newman, B., Selby, J. V., King, M. C., Slemenda, C., Fabsitz, R., and Friedman, G. D. (1987). Concordance for type 2 (non-insulin-dependent) diabetes mellitus in male twins. *Diabetologia*, *30*(10), 763-768.
- Niyonsaba, F., Ogawa, H., and Nagaoka, I. (2004). Human beta-defensin-2 functions as a chemotactic agent for tumour necrosis factor-alpha-treated human neutrophils. *Immunology*, *111*(3), 273-281.
- Niyonsaba, F., Ushio, H., Nakano, N., Ng, W., Sayama, K., Hashimoto, K., Nagaoka, I., Okumura, K., and Ogawa, H. (2007). Antimicrobial peptides human beta-defensins stimulate epidermal keratinocyte migration, proliferation and production of proinflammatory cytokines and chemokines. *Journal of Investigative Dermatology*, *127*(3), 594-604. doi: 10.1038/sj.jid.5700599
- Park, J. Y., Chen, L., Tanner, J.-P., Sellers, T., Lee, J., Dossett, N., Ratnashinge, L., Lang, N., Kadlubar, F., and Ambrosone, C. (2006). The deletion polymorphism of the UDP-glucuronosyltransferase (UGT) 2B17 and risk of prostate cancer in African American and Caucasian men. *Proceedings of the American Association for Cancer Research*, *2006*(1), 865.
- Pezzolesi, M. G., Nam, M., Nagase, T., Klupa, T., Dunn, J. S., Mlynarski, W. M., Rich, S. S., Warram, J. H., and Krolewski, A. S. (2004). Examination of candidate chromosomal regions for type 2 diabetes reveals a susceptibility locus on human chromosome 8p23.1. *Diabetes*, *53*(2), 486-491.
- Pickup, J. C. (2004). Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. *Diabetes Care*, *27*(3), 813-823.
- Pickup, J. C., and Crook, M. A. (1998). Is type II diabetes mellitus a disease of the innate immune system? *Diabetologia*, *41*(10), 1241-1248. doi: 10.1007/s001250051058
- Ptacek, T., Li, X., Kelley, J. M., and Edberg, J. C. (2009). Copy number variants in genetic susceptibility and severity of systemic lupus erythematosus. *Cytogenetic and Genome Research*, *123*(1-4), 142-147. doi: 10.1159/000184701
- Punchard, N. A., Whelan, C. J., and Adcock, I. (2004). The Journal of Inflammation. *The Journal of Inflammation*, *1*(1), 1. doi: 10.1186/1476-9255-1-1

- Quiñones-Mateu, M. E., Lederman, M. M., Feng, Z., Chakraborty, B., Weber, J., Rangel, H. R., Marotta, M. L., Mirza, M., Jiang, B., Kiser, P., Medvik, K., Sieg, S. F., and Weinberg, A. (2003). Human epithelial β -defensins 2 and 3 inhibit HIV-1 replication. *AIDS*, *17*(16), F39-F48.
- Redon, R., Ishikawa, S., Fitch, K. R., Feuk, L., Perry, G. H., Andrews, T. D., Fiegler, H., Shapero, M. H., Carson, A. R., Chen, W., Cho, E. K., Dallaire, S., Freeman, J. L., Gonzalez, J. R., Gratacos, M., Huang, J., Kalaitzopoulos, D., Komura, D., MacDonald, J. R., Marshall, C. R., Mei, R., Montgomery, L., Nishimura, K., Okamura, K., Shen, F., Somerville, M. J., Tchinda, J., Valsesia, A., Woodwark, C., Yang, F., Zhang, J., Zerjal, T., Zhang, J., Armengol, L., Conrad, D. F., Estivill, X., Tyler-Smith, C., Carter, N. P., Aburatani, H., Lee, C., Jones, K. W., Scherer, S. W., and Hurles, M. E. (2006). Global variation in copy number in the human genome. *Nature*, *444*(7118), 444-454. doi: 10.1038/nature05329
- Ridderstråle, M., and Groop, L. (2009). Genetic dissection of type 2 diabetes. *Molecular and Cellular Endocrinology*, *297*(1-2), 10-17. doi: <http://dx.doi.org/10.1016/j.mce.2008.10.002>
- Rizvi, S., Raza, S. T., and Mahdi, F. (2014). Association of genetic variants with diabetic nephropathy. *World Journal of Diabetes*, *5*(6), 809-816. doi: 10.4239/wjd.v5.i6.809
- Rohrl, J., Yang, D., Oppenheim, J. J., and Hehlhans, T. (2010). Human beta-defensin 2 and 3 and their mouse orthologs induce chemotaxis through interaction with CCR2. *The Journal of Immunology*, *184*(12), 6688-6694. doi: 10.4049/jimmunol.0903984
- Rovelet-Lecrux, A., Frebourg, T., Tuominen, H., Majamaa, K., Campion, D., and Remes, A. M. (2007). APP locus duplication in a Finnish family with dementia and intracerebral haemorrhage. *Journal of Neurology, Neurosurgery & Psychiatry*, *78*(10), 1158-1159.
- Ryan, G. B., and Majno, G. (1977). Acute inflammation. A review. *The American Journal of Pathology*, *86*(1), 183-276.
- Sanghera, D. K., and Blackett, P. R. (2012). Type 2 Diabetes Genetics: Beyond GWAS. *Journal of Diabetes and Metabolism*, *3*(198). doi: 10.4172/2155-6156.1000198
- Schena, F. P., and Gesualdo, L. (2005). Pathogenetic mechanisms of diabetic nephropathy. *Journal of American Society of Nephrology*, *16 Suppl 1*, S30-33.
- Schutte, B. C., Mitros, J. P., Bartlett, J. A., Walters, J. D., Jia, H. P., Welsh, M. J., Casavant, T. L., and McCray, P. B., Jr. (2002). Discovery of five conserved beta-defensin gene clusters using a computational search strategy. *Proceedings of the National Academy of Science of United States of America*, *99*(4), 2129-2133. doi: 10.1073/pnas.042692699

- Sebat, J., Lakshmi, B., Troge, J., Alexander, J., Young, J., Lundin, P., Maner, S., Massa, H., Walker, M., Chi, M., Navin, N., Lucito, R., Healy, J., Hicks, J., Ye, K., Reiner, A., Gilliam, T. C., Trask, B., Patterson, N., Zetterberg, A., and Wigler, M. (2004). Large-scale copy number polymorphism in the human genome. *Science*, *305*(5683), 525-528. doi: 10.1126/science.1098918
- Selsted, M. E., and Ouellette, A. J. (2005). Mammalian defensins in the antimicrobial immune response. *Nature Immunology*, *6*(6), 551-557. doi: 10.1038/ni1206
- Sharp, A. J., Locke, D. P., McGrath, S. D., Cheng, Z., Bailey, J. A., Vallente, R. U., Pertz, L. M., Clark, R. A., Schwartz, S., Segraves, R., Oseroff, V. V., Albertson, D. G., Pinkel, D., and Eichler, E. E. (2005). Segmental duplications and copy-number variation in the human genome. *The American Journal of Human Genetics*, *77*(1), 78-88. doi: 10.1086/431652
- Singleton, A., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., and Nussbaum, R. (2003). α -Synuclein locus triplication causes Parkinson's disease. *Science*, *302*(5646), 841-841.
- Spector, W. G., and Willoughby, D. A. (1963). The Inflammatory Response. *Bacteriological Reviews*, *27*(2), 117-154.
- Stankiewicz, P., and Lupski, J. R. (2010). Structural variation in the human genome and its role in disease. *Annual Review of Medicine*, *61*, 437-455. doi: 10.1146/annurev-med-100708-204735
- Stuart, P. E., Huffmeier, U., Nair, R. P., Palla, R., Tejasvi, T., Schalkwijk, J., Elder, J. T., Reis, A., and Armour, J. A. L. (2012). Association of [beta]-Defensin Copy Number and Psoriasis in Three Cohorts of European Origin. *Journal of Investigative Dermatology*, *132*(10), 2407-2413. doi: <http://www.nature.com/jid/journal/v132/n10/supinfo/jid2012191s1.html>
- Taudien, S., Galgoczy, P., Huse, K., Reichwald, K., Schilhabel, M., Szafranski, K., Shimizu, A., Asakawa, S., Frankish, A., Loncarevic, I., Shimizu, N., Siddiqui, R., and Platzer, M. (2004). Polymorphic segmental duplications at 8p23.1 challenge the determination of individual defensin gene repertoires and the assembly of a contiguous human reference sequence. *BMC Genomics*, *5*(1), 92.
- Taudien, S., Groth, M., Huse, K., Petzold, A., Szafranski, K., Hampe, J., Rosenstiel, P., Schreiber, S., and Platzer, M. (2010). Haplotyping and copy number estimation of the highly polymorphic human beta-defensin locus on 8p23 by 454 amplicon sequencing. *BMC Genomics*, *11*, 252. doi: 10.1186/1471-2164-11-252
- Tong, P. C., Lee, K. F., So, W. Y., Ng, M. H., Chan, W. B., Lo, M. K., Chan, N. N., and Chan, J. C. (2004). White blood cell count is associated with macro- and microvascular complications in chinese patients with type 2 diabetes. *Diabetes Care*, *27*(1), 216-222.

- Tuzun, E., Sharp, A. J., Bailey, J. A., Kaul, R., Morrison, V. A., Pertz, L. M., Haugen, E., Hayden, H., Albertson, D., Pinkel, D., Olson, M. V., and Eichler, E. E. (2005). Fine-scale structural variation of the human genome. *Nature Genetics*, *37*(7), 727-732. doi: 10.1038/ng1562
- Tyson, J., Majerus, T. M. O., Walker, S., and Armour, J. A. L. (2010). Screening for common copy-number variants in cancer genes. *Cancer Genetics and Cytogenetics*, *203*(2), 316-323. doi: <http://dx.doi.org/10.1016/j.cancergencyto.2010.08.008>
- van Tilburg, J., van Haeften, T. W., Pearson, P., and Wijmenga, C. (2001). Defining the genetic contribution of type 2 diabetes mellitus. *Journal of Medical Genetics*, *38*(9), 569-578.
- Wain, L. V., Armour, J. A., and Tobin, M. D. (2009). Genomic copy number variation, human health, and disease. *Lancet*, *374*(9686), 340-350. doi: 10.1016/s0140-6736(09)60249-x
- Wain, L. V., Odenthal-Hesse, L., Abujaber, R., Sayers, I., Beardsmore, C., Gaillard, E. A., Chappell, S., Dogaru, C. M., McKeever, T., Guetta-Baranes, T., Kalsheker, N., Kuehni, C. E., Hall, I. P., Tobin, M. D., and Hollox, E. J. (2014). Copy Number Variation of the Beta-Defensin Genes in Europeans: No Supporting Evidence for Association with Lung Function, Chronic Obstructive Pulmonary Disease or Asthma. *PLoS One*, *9*(1), e84192. doi: 10.1371/journal.pone.0084192
- Walker, S., Janyakhtikul, S., and Armour, J. A. (2009). Multiplex Paralogue Ratio Tests for accurate measurement of multiallelic CNVs. *Genomics*, *93*(1), 98-103. doi: 10.1016/j.ygeno.2008.09.004
- Wang, Y., Ng, M. C. Y., So, W.-Y., Ma, R., Ko, G. T. C., Tong, P. C. Y., and Chan, J. C. N. (2005). Association between tumour necrosis factor- α G-308A polymorphism and risk of nephropathy in obese Chinese type 2 diabetic patients. *Nephrology Dialysis Transplantation*, *20*(12), 2733-2738. doi: 10.1093/ndt/gfi101
- Watanabe, R. M., Allayee, H., Xiang, A. H., Trigo, E., Hartiala, J., Lawrence, J. M., and Buchanan, T. A. (2007). Transcription factor 7-like 2 (TCF7L2) is associated with gestational diabetes mellitus and interacts with adiposity to alter insulin secretion in Mexican Americans. *Diabetes*, *56*(5), 1481-1485.
- Weinberg, A., Krisanaprakornkit, S., and Dale, B. A. (1998). Epithelial antimicrobial peptides: review and significance for oral applications. *Critical Reviews in Oral Biology and Medicine*, *9*(4), 399-414.
- Wellcome Trust Case Control, C. (2010). Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. *Nature*, *464*(7289), 713-720. doi: 10.1038/nature08979
- Wiesner, J., and Vilcinskas, A. (2010). Antimicrobial peptides: The ancient arm of the human immune system. *Virulence*, *1*(5), 440-464.

- Willcocks, L. C., Lyons, P. A., Clatworthy, M. R., Robinson, J. I., Yang, W., Newland, S. A., Plagnol, V., McGovern, N. N., Condliffe, A. M., and Chilvers, E. R. (2008). Copy number of FCGR3B, which is associated with systemic lupus erythematosus, correlates with protein expression and immune complex uptake. *The Journal of Experimental Medicine*, 205(7), 1573-1582.
- Xue, Y., Sun, D., Daly, A., Yang, F., Zhou, X., Zhao, M., Huang, N., Zerjal, T., Lee, C., Carter, N. P., Hurles, M. E., and Tyler-Smith, C. (2008). Adaptive evolution of UGT2B17 copy-number variation. *The American Journal of Human Genetics*, 83(3), 337-346. doi: 10.1016/j.ajhg.2008.08.004
- Yang, Y., Chung, E. K., Wu, Y. L., Savelli, S. L., Nagaraja, H. N., Zhou, B., Hebert, M., Jones, K. N., Shu, Y., Kitzmiller, K., Blanchong, C. A., McBride, K. L., Higgins, G. C., Rennebohm, R. M., Rice, R. R., Hackshaw, K. V., Roubey, R. A., Grossman, J. M., Tsao, B. P., Birmingham, D. J., Rovin, B. H., Hebert, L. A., and Yu, C. Y. (2007). Gene copy-number variation and associated polymorphisms of complement component C4 in human systemic lupus erythematosus (SLE): low copy number is a risk factor for and high copy number is a protective factor against SLE susceptibility in European Americans. *The American Journal of Human Genetics*, 80(6), 1037-1054. doi: 10.1086/518257
- Zelmanovitz, T., Gerchman, F., Balthazar, A. P., Thomazelli, F. C., Matos, J. D., and Canani, L. H. (2009). Diabetic nephropathy. *Diabetology and Metabolic Syndrome*, 1(1), 10. doi: 10.1186/1758-5996-1-10
- Zhang, X., Muller, S., Moller, M., Huse, K., Taudien, S., Book, M., Stuber, F., Platzer, M., and Groth, M. (2014). 8p23 beta-defensin copy number determination by single-locus pseudogene-based paralog ratio tests risk bias due to low-frequency sequence variations. *BMC Genomics*, 15, 64. doi: 10.1186/1471-2164-15-64
- Zhou, X. J., Cheng, F. J., Lv, J. C., Luo, H., Yu, F., Chen, M., Zhao, M. H., and Zhang, H. (2012). Higher DEFB4 genomic copy number in SLE and ANCA-associated small vasculitis. *Rheumatology (Oxford)*, 51(6), 992-995. doi: 10.1093/rheumatology/ker419